The Patent Finder

Terms ending in 2042

Purdue Pharma L.P.

Every in-force patent on Purdue Pharma L.P.'s record whose computed term ends in 2042, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleHolderStatusExpiresConfidence
US 12,653,808Compounds for Treating Multiple Myeloma
In force
 · High confidence
Knoa Pharma LLCIn forceHigh confidence
US 12,371,427Polymorphic Forms of a Substituted-Quinoxaline-Type Bridged-Piperidine Compound
In force
 · High confidence
Knoa Pharma LLCIn forceHigh confidence
US 12,377,076Compounds for Treating Lymphoma or a T-Cell Malignant Disease
In force
 · High confidence
Knoa Pharma LLCIn forceHigh confidence
3 of 3 patents shown. Soonest term end first, then patent number.
1 of these is in force and held by Purdue Pharma L.P..
Updated Nov 20, 2026 · includes USPTO assignment data published Nov 19, 2026, status data published Nov 20, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 20, 2026 · includes USPTO assignment data published Nov 19, 2026, status data published Nov 20, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited